| Endometriosis
Orilissa vs Zoladex
Side-by-side clinical, coverage, and cost comparison for endometriosis.Deep comparison between: Orilissa vs Zoladex with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZoladex has a higher rate of injection site reactions vs Orilissa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zoladex but not Orilissa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Orilissa
Zoladex
At A Glance
Oral
Once or twice daily
GnRH receptor antagonist
SC injection
Every 28 days
GnRH agonist
Indications
- Endometriosis
- Prostate carcinoma
- Endometriosis
- Abnormal uterine bleeding
- Breast Carcinoma
Dosing
Endometriosis 150 mg once daily for up to 24 months, taken orally at approximately the same time each day with or without food.
Endometriosis with dyspareunia Consider 200 mg twice daily for up to 6 months, taken orally.
Endometriosis with moderate hepatic impairment (Child-Pugh Class B) 150 mg once daily for up to 6 months; 200 mg twice daily is not recommended.
Prostate carcinoma (Stage B2-C) 3.6 mg SC every 28 days starting 8 weeks before radiotherapy, in combination with flutamide, continued during radiation therapy; alternatively, a 10.8 mg depot may follow the initial 3.6 mg depot.
Prostate carcinoma (advanced) 3.6 mg SC every 28 days; intended for long-term administration.
Endometriosis 3.6 mg SC every 28 days for 6 months.
Abnormal uterine bleeding One or two 3.6 mg SC depots given 4 weeks apart; surgery performed at 4 weeks after one depot, or within 2-4 weeks after the second depot.
Breast Carcinoma 3.6 mg SC every 28 days; intended for long-term administration.
Contraindications
- Pregnancy (exposure early in pregnancy may increase risk of early pregnancy loss)
- Known osteoporosis (risk of further bone loss)
- Severe hepatic impairment (Child-Pugh C)
- Concomitant use of OATP1B1 inhibitors known or expected to significantly increase elagolix plasma concentrations
- Known hypersensitivity reaction to elagolix or any inactive component (including anaphylaxis and angioedema)
- Known hypersensitivity to GnRH, GnRH agonist analogues, or any component of ZOLADEX
- Pregnancy (except when used for palliative treatment of advanced breast cancer)
Adverse Reactions
Most common (>=5%) Hot flush, headache, nausea, insomnia, mood altered/mood swings, amenorrhea, depressed mood/depression, anxiety, arthralgia
Serious Bone loss, change in menstrual bleeding pattern, suicidal ideation and suicidal behavior, exacerbation of mood disorders, hepatic transaminase elevations
Postmarketing Hypersensitivity reactions including anaphylaxis, angioedema, and urticaria
Most common (>10%) in men Hot flashes, sexual dysfunction, decreased erections, lower urinary tract symptoms
Most common (>20%) in women Hot flushes, headache, sweating, acne, emotional lability, depression, decreased libido, vaginitis, breast atrophy, seborrhea, peripheral edema
Serious Tumor flare, ureteral obstruction, spinal cord compression, pituitary apoplexy
Postmarketing Osteoporosis, bone fracture, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, transient ischemic attack, ovarian cyst, pituitary adenoma, SJS/TEN, DRESS, AGEP, erythema multiforme, psychotic disorders, suicidal ideation, convulsions
Pharmacology
GnRH receptor antagonist; elagolix competitively binds GnRH receptors in the pituitary gland, causing dose-dependent suppression of LH and FSH and reducing ovarian estradiol and progesterone concentrations.
ZOLADEX is a synthetic decapeptide analogue of GnRH that inhibits pituitary gonadotropin secretion; chronic administration suppresses serum testosterone in males to castrate levels and reduces serum estradiol in females to postmenopausal levels, leading to regression of hormone-sensitive tumors and accessory sex organ regression.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Orilissa
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (10/12)
Zoladex
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Orilissa
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (5/8) · Qty limit (7/8)
Zoladex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Orilissa
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Zoladex
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
myAbbVie Assist: Women's HealthCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Zoladex.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OrilissaView full Orilissa profile
ZoladexView full Zoladex profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.